Galantamine Effects on Cognitive Function in Marijuana Users
Completed · Phase 1 · Has a placebo group
Conditions studied: Memory
In brief
To evaluate galantamine's effects on cognitive performance in marijuana users. Galantamine, an acetylcholine esterase inhibitor, is approved for treatment of Alzheimer's disease. Current marijuana users show impaired cognitive functioning, which predicts poor treatment response to behavioral treatments in this population. Whether cognitive impairment in marijuana users will improve with medication treatment has not been evaluated. We hypothesize that galantamine, compared to placebo, will improve cognitive performance in marijuana users.Galantamine, compared to placebo, will improve working memory, verbal learning/memory and response inhibition functions in marijuana users.
Key facts
- Study ID
- NCT00969696
- Run by
- Yale University
- People needed
- 29
- Starts
- 2009-08-01
- Expected to finish
- 2011-07-01
- Last updated by the study team
- 2012-07-25
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Men and women between the ages of 18 and 55 who are dependent on or abuse marijuana, according to DSM-IV criteria;
- History of marijuana use on the average of at least twice a week over a one-month period;
- Current marijuana use, indicated by positive urine toxicology for marijuana;
- No current medical problems and normal ECG;
- For women, neither pregnant as determined by pregnancy screening nor breast feeding, and using acceptable birth control methods.
You may not qualify if…
- Current major psychiatric illnesses including mood, psychotic, or anxiety disorders;
- Current dependence to other drugs of abuse or alcohol (except nicotine or marijuana dependence);
- History of major medical illnesses including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances or other medical conditions that the study physician deems contraindicated for the subject to be in the study;
- Use of other medications including a) drugs that slow heart rate (eg, beta-blockers),which may increase the risk of bradycardia and AV block and b) NSAIDs; increased potential for developing ulcers/active or occult gastrointestinal bleeding;
- Known allergy to galantamine
Where it is running
- Department of Veterans Affairs — West Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.